Cancer

Capital Rx Unveils Healthcare’s First Unified Pharmacy and Medical Claims Processing Platform

Judi Health™ enables unified claim processing to enhance patient experience, improve outcomes, and reduce premiums NEW YORK, Feb. 10, 2025…

11 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will…

11 months ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2…

11 months ago

Oncocyte Prices $29.1 Million Equity Offering

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial LaunchStrategic Partner Bio-Rad Invests, Boosts Support for Trial…

11 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for…

11 months ago

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer 

Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology…

11 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…

11 months ago

Qu Biologics’ Immunomodulator Clears Senescence

BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs),…

11 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

        Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds…

11 months ago

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) --…

11 months ago